Improvement in the outcome of rejection with pentoxifylline in renal transplantation: A randomized

Transplantation

Volumn 65, Issue 3, 1998, Pages 385-389

  Noel, Christian ^a   Hazzan, Marc ^a   Labalette, Myriam ^b   Coppin, Marie Christine ^b   Jude, Brigitte ^b   Dessaint, Jean Paul ^b   Lelievre, Gaston ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Ctr Hosp Reg Universitaire ^*

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; CYTOKINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIBODY; MEPREDNISONE; METHYLXANTHINE DERIVATIVE; OKT 3; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; REACTIVE OXYGEN METABOLITE;

ADJUVANT THERAPY; ADULT; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PENTOXIFYLLINE; PLACEBOS; POSTOPERATIVE COMPLICATIONS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TIME FACTORS; VASODILATOR AGENTS;

EID: 0032519895     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199802150-00015     Document Type: Article

References (25)

1. Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989; 142: 1274.
2. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230.
3. Han J, Thompson P, Beutler B. Dexamethazone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391.
4. Zabel P, Schonharting MM, Wolter DT, Schade UF. Oxpentifylline in endotoxemia. Lancet 1989; 50: 1474.
5. Alegre ML, Gastaldello K, Abramowicz D, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674.
6. Bachmann S, Caldwell-Kenkel JC, Currin RT, et al. Protection by pentoxifylline against graft failure from storage injury after orthotopic rat liver transplantation with arterialization. Transpl Int 1992; 5: S345.
7. Kozaki K, Egawa H, Bermudes L, Feduska NJ, So S, Esquivel CO. Pentoxifylline inhibits production of superoxide anion and tumor necrosis factor by Kupffer cells in rat liver preservation. Transplant Proc 1993; 25: 3025.
8. Peng XX, Currin RT, Thurman RG, Lemasters JJ. Protection by pentoxifylline against normothermic liver ischemia/reperfusion in rats. Transplantation 1995; 59: 1537.
9. Van Leenen D, Van Der Poll T, Levi M, et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151: 2318.
10. Berens KL, Luke DR. Pentoxifylline in isolated perfused rat kidney. Transplantation 1990; 49: 876.
11. Brunner LJ, Vadiei K, Iyer LV, Luke DR. Prevention of CsA induced nephrotoxicity with pentoxifylline. Ren Fail 1989; 11: 97.
12. Carrier M, Perrault LP, Tronc F, Stewart DI, Pelletier CL. Pentoxifylline decreases cyclosporine-induced renal endothelin release and vasoconstriction. Ann Thorac Surg 1993; 55: 490.
13. Bennett WM, Elzinga LW, Porter GA, Rosen S. The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity. Transplantation 1992; 54: 1118.
14. Ates E, Sharma P, Erkasap S, et al. Cyclosporine nephrotoxicity in the ischemic kidney and the protective effect of pentoxyfylline: a study in the rat. Transplantation 1996; 62: 864.
15. Copin MC, Noël C, Hazzan M, et al. Diagnostic and predictive value of an immunohistochemical profile in asymptomatic acute rejection of renal allografts. Transplant Immunol 1995; 3: 229.
16. Königsrainer A, Aichberger C, Riedman B, Steurer W, Ofner D, Margreiter R. Pentoxifylline as an adjunct to cyclosporine-based immunosuppression does not improve the outcome of renal transplantation. Transplant Proc 1995; 27: 1062.
17. Endres S, Fülle HJ, Sinha B, et al. Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor α and interleukin-1β by human mononuclear cells. Immunology 1991; 72: 56.
18. Khabar KSA, Dzimiri M, Parhar RS, et al. Pentoxifylline (PTX) selectively potentiates cyclosporine (CsA)-mediated suppression of cell-mediated lymphototoxicity: median-effect analysis for the drug dose reductions in PTX and CsA combination treatment. Transplantation 1996; 61: 838.
19. Bianco JA, Almgren J, Kern DL, et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991; 51: 925.
20. Krams SM, Falco DA, Villanueva JC, et al. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation 1992; 53: 151.
21. Thanhäuser A, Reiling N, Böhle A, et al. Pentoxifylline: a potent inhibitor of IL2 and IFNγ biosynthesis and BCG-induced cytotoxicity. Immunology 1993; 50: 151.
22. Staak K, Prösch S, Stein J, et al. Pentoxifylline promotes replication of human cytomegalovirus in vivo and in vitro. Blood 1997; 89: 3182.
23. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50.
24. Sullivan GW, Carper HT, Novick WJ, Mandell GL. Inhibition of the inflammatory action of interleukin 1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988; 56: 1722.
25. Tilg H, Eibp B, Pichl M, et al. Immune response modulation by pentoxifylline in vitro. Transplantation 1993; 56: 196.